PulseJournal ClubResearchersJournalsExplore
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 7, 2026Clinical Cancer ResearchOpen Access

Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMario E. LacoutureAPAlexander PanTMTara Maier

Discussion

Loading...

Member takes

Overview

Nonrandomized phase 2 trial demonstrates benralizumab improves health-related quality of life in patients with eosinophil-related cutaneous adverse events from cancer therapy.

Key Points

  • This research aims to evaluate the efficacy and safety of benralizumab for treating eosinophil-related cutaneous adverse events after systemic cancer therapies.
  • Single-arm, single-center, open-label, phase 2 trial
  • Involved patients with cancer experiencing systemic therapy-associated eosinophil-related cutaneous adverse events
  • Benralizumab 30 mg administered subcutaneously every 4 weeks for 3 doses, followed by every 8 weeks for 3 doses
  • 76% of evaluable patients showed clinical response after treatment by Week 4
  • Median grade of eosinophil-related cutaneous adverse events decreased from 2 to 1 (P < .0001)
  • Patients reported improvements in health-related quality of life and reduced rash body surface area

Cite This Study

Lacouture et al. (2026) studied this question.

synapsesocial.com/papers/69fbef86164b5133a91a36cbhttps://doi.org/10.1158/1078-0432.ccr-25-2764
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Eosinophils from Physiology to Disease: A Comprehensive Review2018 · 323 citations
  2. 2Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer2019 · 2,647 citations
  3. 3Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis2023 · 19 citations